Multiplex assays, which can measure immunoglobulin E to several allergens simultaneously in a single assay, have emerged as an alternative to traditional skin testing and singleplex assays.Not currently approved for clinical use in the United States, Immuno Solid-Phase Allergen Chip and other multiplex assays are approved and used as part of clinical practice in Europe and Asia.The advantages of multiplex technology, including the extensive immunoglobulin E profiling afforded from only a small sample of serum, have to be balanced against considerations of cost, sensitivity, and extraneous data.The major strength of multiplex assays at this time likely remains for research applications; however, ongoing advances and innovations in multiplex technology can eventually be expected to be integrated as an important tool in clinical diagnosis and management.